Ligand ID: TAC


Drugbank ID:
DB00759
(Tetracycline)


Indication:
Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.

Get human targets for TAC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'TAC'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.61A10.68
19.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		1q2w 3C-LIKE PROTEASE
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.59A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		1wnc E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU E 941
LEU D 930
VAL D 934
LEU F 941
VAL F 933
1.57A17.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		1x7q BETA-2-MICROGLOBULIN
HLA, A-11
(Homo
sapiens)		4 / 7
THR A  94
SER A  92
PRO B  32
LEU B  64
1.41A11.34
20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		1x7q HLA, A-11
(Homo
sapiens)		5 / 12
TYR A 159
ILE A  52
TYR A   7
TYR A  59
GLU A  63
1.44A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		1x7q BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 11
SER B  28
PHE B  62
HIS B  31
ILE B  35
SER B  33
1.78A19.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		1z1i 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.58A10.75
19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B1098
SER B1094
ASP B1033
VAL B1091
1.66A10.75
18.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		1zv8 E2 GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU H  30
PHE I   9
GLN I  17
GLN I  15
ILE K  13
1.78A11.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.60A21.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.61A10.71
18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		5 / 12
PRO F 121
ILE F 125
PHE F 152
TYR F 154
TYR F 143
1.45A22.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2alv REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2amd 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.63A10.56
18.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2amq 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.58A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2cjr NUCLEOCAPSID PROTEIN
(SARS-COV
TW1)		5 / 11
LEU G 353
LEU G 340
LEU G 292
ILE G 338
ILE G 358
1.47A19.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		2cme HYPOTHETICAL PROTEIN
5
(SARSr-CoV)		4 / 7
SER E  72
SER E  56
VAL F  93
LEU F  53
1.47A16.88
14.11
None
None
None
D10  F1099 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 177
ASP H 144
PRO H 119
VAL H 150
1.64A15.24
19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 7
THR S 363
SER L  93
SER L  94
LEU S 412
1.18A12.50
20.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2dd8 IGG LIGHT CHAIN
(Homo
sapiens)		4 / 6
SER L 138
ASP L 139
PRO L 114
VAL L 197
1.59A11.83
21.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		2dd8 IGG HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 205
PRO H 202
VAL H  11
LEU H 175
1.36A15.24
19.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		2g9t ORF1A POLYPROTEIN
(SARSr-CoV)		4 / 7
THR Q 111
PRO Q 107
VAL Q  42
LEU Q  14
1.19A16.89
17.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2ghv SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU C 421
PHE C 379
ARG C 342
VAL C 328
ILE C 345
1.65A21.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 11
SER A 273
ASN A  74
PRO A 343
VAL A 275
ILE A 322
1.75A22.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 12
SER A 273
ASN A  74
PRO A 343
VAL A 275
ILE A 322
1.73A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 12
VAL A  51
ILE A  27
TYR A  32
GLU A  41
ILE A  42
1.75A19.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		5 / 11
SER A 273
ASN A  74
PRO A 343
VAL A 275
ILE A 322
1.79A22.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2jzd REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
LEU A 603
LEU A 596
ILE A 560
VAL A 574
ILE A 573
1.37A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2kqv NSP3
(SARSr-CoV)		5 / 11
LEU A  81
LEU A  74
ILE A  38
VAL A  52
ILE A  51
1.28A24.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.60A10.71
18.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2op9 REPLICASE
POLYPROTEIN 1AB
(PP1AB, ORF1AB)
3C-LIKE PROTEINASE
(3CL-PRO, 3CLP)
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.59A21.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 7
THR C 120
SER A 315
ASP C  78
LEU C 189
1.30A10.12
23.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
LEU B 245
LEU B 254
ILE B 269
VAL B 275
ILE B 295
1.55A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2qcy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.60A20.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2qiq REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.54A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
VAL C  51
ILE C  27
TYR C  32
GLU C  41
ILE C  42
1.73A19.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
SER E 273
ASN E  74
PRO E 343
VAL E 275
ILE E 322
1.51A23.01
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 12
SER E 273
ASN E  74
PRO E 343
VAL E 275
ILE E 322
1.48A21.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		5 / 11
SER D 273
ASN D  74
PRO D 343
VAL D 275
ILE D 322
1.56A21.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2rnk REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 11
LEU A 603
LEU A 596
ILE A 560
VAL A 574
ILE A 573
1.25A17.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.63A10.79
19.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2vj1 MAIN PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		2w2g NSP3
(SARSr-CoV)		4 / 6
SER A 637
ASP A 639
SER A 636
VAL A 635
1.56A12.33
21.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2w2g NSP3
(SARSr-CoV)		5 / 11
LEU A 603
LEU A 596
ILE A 560
VAL A 574
ILE A 573
1.31A22.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.76A21.40
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.79A21.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.77A23.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.76A23.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.75A21.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.77A21.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		2zu5 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.57A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3bgf F26G19 FAB
(Mus
musculus)		4 / 7
THR H 184
SER L 116
VAL L 133
LEU H 154
1.34A10.48
21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_B_TACB1888_1
(ELONGATION FACTOR
EF-TU)		3bgf F26G19 FAB
(Mus
musculus)		4 / 5
THR B 167
SER B 180
PRO B 169
SER C 176
1.76A10.48
21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		3d0h ACE2
SPIKE GLYCOPROTEIN
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 12
TYR B  34
TYR F 442
ILE F 397
TYR F 481
TYR F 408
1.76A17.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		3d62 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.55A22.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		3e91 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.60A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		3e91 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.63A10.40
19.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
ASP B 155
PRO B  99
VAL B  13
LEU B 177
1.42A10.40
19.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.48A20.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		3f9f 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.63A10.68
19.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		3f9g 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.64A10.68
18.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		3fzd 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.56A21.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3i6g BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		4 / 7
THR A  94
SER A  92
PRO B  32
LEU B  64
1.31A10.12
20.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		3i6l BETA-2-MICROGLOBULIN
(Homo
sapiens)		5 / 11
SER E  28
PHE E  62
HIS E  31
ILE E  35
SER E  33
1.75A18.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		4 / 7
THR D  94
SER D  92
PRO E  32
LEU E  64
1.38A10.53
22.10
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		3m3s 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.62A10.75
19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.79A22.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 11
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.78A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 12
ASN A 196
PHE A 193
PRO A  12
GLN A   3
ILE A 237
1.77A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3sck ACE2
SPIKE GLYCOPROTEIN
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 7
SER B  19
ASP F 463
PRO F 462
LEU B  79
1.30A5.43
19.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		3snd 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 7
ASP A 155
PRO A  99
VAL A  13
LEU A 177
1.49A10.75
19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.58A20.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		4hi3 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.65A10.71
19.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		4mds 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A21.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		4mds 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR A  98
SER A  94
ASP A  33
VAL A  91
1.63A10.75
18.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		4mm3 PAPAIN-LIKE
PROTEINASE
(SARSr-CoV)		4 / 7
SER B  61
ASP B  62
VAL B  58
LEU B  21
1.31A8.03
21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		4mm3 PAPAIN-LIKE
PROTEINASE
(SARSr-CoV)		4 / 6
THR B 302
ASP B 303
SER B 116
VAL B 117
1.66A8.03
21.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)		5 / 12
LEU B 124
SER B 241
PHE B 305
ARG B 167
VAL B 206
1.76A19.44
None
None
None
DMS  A 903 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		4ovz PAPAIN-LIKE
PROTEINASE
(SARS-COV
Urbani)		5 / 12
VAL A 304
TYR A 306
TYR A 214
TYR A 252
TYR A 208
1.78A22.85
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		4 / 7
ASP A 262
PRO A 261
VAL A 255
LEU A 290
1.41A11.64
21.49
None
None
PO4  A 404 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		4tww 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
THR B  98
SER B  94
ASP B  33
VAL B  91
1.62A10.75
19.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		4twy 3C-LIKE PROTEINASE
(SARSr-CoV)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.58A21.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 11
LEU D 383
LEU D 442
VAL D 316
ILE D 502
VAL D 312
1.55A15.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		5c8s NSP10
(SARSr-CoV)		4 / 7
THR C 111
PRO C 107
VAL C  42
LEU C  14
1.42A18.46
17.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8s GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
LEU B 366
HIS B 373
SER B 369
PHE B 377
VAL B 389
1.75A17.06
None
None
None
None
SAH  B 605 (-4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5c8t GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
LEU B 366
HIS B 373
SER B 369
PHE B 377
VAL B 389
1.74A17.06
None
None
None
None
SAM  B 605 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5c8u GUANINE-N7
METHYLTRANSFERASE
(SARSr-CoV)		5 / 12
PRO D 443
TYR D 494
TYR D 446
ILE D 474
TYR D 447
1.74A18.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
VAL D 304
TYR D 306
TYR D 214
TYR D 252
TYR D 208
1.78A22.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		5e6j REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
THR A 302
ASP A 303
SER A 116
VAL A 117
1.61A7.67
21.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 12
LEU C 366
HIS C 373
SER C 369
PHE C 377
VAL C 389
1.65A17.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 12
VAL B 304
TYR B 306
TYR B 214
TYR B 252
TYR B 208
1.74A22.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		5tl7 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
THR B 302
ASP B 303
SER B 116
VAL B 117
1.65A8.03
21.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.59A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x4r S PROTEIN
(MERS-CoV)		5 / 12
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.58A18.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5x4r S PROTEIN
(MERS-CoV)		6 / 12
PRO A 145
VAL A 118
TYR A 293
ILE A 143
TYR A  87
ILE A 295
1.72A22.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		5x4r S PROTEIN
(MERS-CoV)		5 / 11
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.61A22.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
TYR A 256
ILE A 234
TYR A 252
PHE A 103
ILE A  87
1.77A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
TYR A 256
ILE A 234
TYR A 252
PHE A 103
ILE A  87
1.75A12.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		5x59 S PROTEIN
(MERS-CoV)		5 / 11
SER B 268
PHE B 281
PRO B 145
VAL B 118
ILE B 256
1.61A9.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		5x59 S PROTEIN
(MERS-CoV)		4 / 6
SER B 299
PRO B 297
SER B  88
VAL B  86
1.64A3.77
13.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_B_TACB1888_1
(ELONGATION FACTOR
EF-TU)		5x59 S PROTEIN
(MERS-CoV)		4 / 5
SER C 365
ASP A 805
PRO C 658
SER C 656
1.79A3.77
13.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
THR A 760
ASP A 757
PRO A 845
VAL A 842
1.42A3.69
13.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 12
LEU A 132
ASN A 129
VAL A 114
ILE A 226
SER A 105
1.77A10.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
THR A 760
ASP A 757
PRO A 845
LEU A 930
1.33A3.69
13.98
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 11
LEU B 224
LEU B 194
ILE B 152
VAL B 124
ILE B 125
1.60A9.79
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
SER C 268
PHE C 281
PRO C 145
VAL C 118
ILE C 256
1.58A9.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5x5c S PROTEIN
(MERS-CoV)		5 / 12
VAL B 631
TYR B 641
TYR B 642
ILE C 333
PHE C 279
1.71A11.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		5x5c S PROTEIN
(MERS-CoV)		5 / 11
LEU B 347
HIS C 836
LEU C 840
LEU B 344
ILE B 662
1.26A9.43
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5x5f S PROTEIN
(MERS-CoV)		5 / 11
SER A 268
PHE A 281
PRO A 145
VAL A 118
ILE A 256
1.59A9.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		5x5f S PROTEIN
(MERS-CoV)		4 / 7
THR C 961
SER C 975
VAL C1124
LEU C 951
1.48A3.77
13.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU B 504
SER B 380
ARG B 315
PRO B 565
GLN B 550
1.36A10.92
LEU  B 504 ( 0.6A)
SER  B 380 ( 0.0A)
ARG  B 315 ( 0.6A)
PRO  B 565 ( 1.1A)
GLN  B 550 ( 0.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 7
THR A 302
ASP A 303
SER A 116
LEU A 163
1.41A7.67
19.84
GOL  A 408 (-3.6A)
None
NA  A 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		5y3e REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		5 / 12
VAL A 304
TYR A 306
TYR A 214
TYR A 252
TYR A 208
1.78A22.81
None
GOL  A 407 (-4.8A)
None
GOL  A 407 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		5y3q REPLICASE
POLYPROTEIN 1A
(SARSr-CoV)		4 / 6
THR A 302
ASP A 303
SER A 116
VAL A 117
1.65A7.67
19.84
GOL  A 409 (-3.5A)
None
NA  A 404 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6acd SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
THR B 760
ASP B 757
PRO B 845
VAL B 842
1.57A3.64
13.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
VAL B 196
ILE B 228
PHE B 161
ILE B 125
TYR B 163
1.45A12.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6acj SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU B1045
SER B1033
PHE B 909
GLN B1036
VAL B 860
1.65A10.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER A 303
ASN C 746
VAL A 581
GLN A 301
SER C 717
1.70A10.90
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
SER A 303
ASN C 746
VAL A 581
GLN A 301
SER C 717
1.68A10.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6ack ACE2
(Homo
sapiens)		5 / 12
ASN D 397
TYR D 217
TYR D 207
ILE D 233
ILE D 513
1.70A18.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 11
LEU B1031
VAL B1047
LEU B 788
ILE B 905
ILE B 913
1.56A9.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
THR B 567
PRO B 565
SER B 516
LEU B 538
1.48A3.69
13.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
TYR B 256
ILE B 234
TYR B 252
PHE B 103
ILE B  87
1.71A13.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs1 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
SER A 303
ASN B 746
VAL A 581
GLN A 301
SER B 717
1.66A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
SER B 541
ASP B 572
PRO B 540
SER B 542
1.38A3.69
13.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
LEU C 224
LEU C 194
ILE C 152
VAL C 124
ILE C 125
1.55A10.29
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
LEU C 788
ASN C 783
PHE C 784
GLN C 786
ILE C 913
1.61A10.48
None
NAG  C1316 (-1.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_B_TACB1888_1
(ELONGATION FACTOR
EF-TU)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 5
SER B 541
ASP B 572
PRO B 540
SER B 542
1.39A3.69
13.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 12
PRO C1061
VAL C1076
TYR A 886
ILE C1114
TYR A 899
1.45A13.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 11
SER B 785
ASN B 783
PHE B 784
GLN B 786
ILE B 913
1.60A10.86
None
NAG  B1316 (-1.8A)
None
NAG  B1316 (-3.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6cs2 SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
THR A 567
PRO A 565
SER A 516
LEU A 538
1.24A3.69
13.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
THR A  94
SER A  92
PRO B  32
LEU B  64
1.34A9.87
20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
LEU A1166
SER B 968
PHE A 970
GLN B 965
ILE A1172
1.69A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.60A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m17 ACE2
(Homo
sapiens)		5 / 11
VAL B 647
LEU B 725
ILE B 694
VAL B 700
ILE B 704
1.53A14.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m17 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 11
LEU A  88
VAL A 505
LEU A  11
ILE A 518
VAL A 511
1.56A14.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 7
SER A 291
PRO A  33
SER A 288
LEU A 458
1.43A4.79
18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m1d ACE2
(Homo
sapiens)		4 / 7
SER D 646
SER D 645
VAL D 670
LEU D 675
1.36A3.90
16.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 6
THR C 185
SER C 188
ASP C 189
VAL C 582
1.59A4.79
18.31
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m1d ACE2
(Homo
sapiens)		5 / 12
HIS D 373
SER D 409
PHE D 314
PRO D 415
SER D 545
1.78A13.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
VAL A 393
PHE A 253
GLU A 391
ILE A 325
TYR A 322
1.77A18.71
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6m1d ACE2
(Homo
sapiens)		5 / 11
HIS D 373
SER D 409
PHE D 314
PRO D 415
SER D 545
1.79A14.72
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 12
LEU A  61
HIS A  65
GLN A 274
VAL A 275
ILE A 545
1.59A15.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.59A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU C  30
VAL C  13
CYH C 160
VAL C 157
ILE C 152
1.67A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
SER C  10
PRO C   9
VAL A 125
LEU A  30
1.77A9.68

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 296
LEU A 220
THR A 304
SER A 301
1.76A19.66

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU D  30
VAL D  13
CYH D 160
VAL D 157
ILE D 152
1.66A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU D  91
LEU C  20
VAL C  66
LEU D  95
ILE C  68
1.79A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 567
SER A 561
VAL A 560
LEU A 663
1.65A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU B  95
LEU A 366
VAL A 335
LEU B  98
VAL A 342
1.70A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 6
SER A 681
VAL A 560
THR A 556
SER A 682
1.58A17.19
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.53A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.61A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.67A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
HIS A 381
LEU A 366
CYH A 563
ILE A 562
VAL B  83
1.70A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A 662
LEU A 351
THR A 531
SER A 564
1.73A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  56
LEU C  28
VAL C  58
LEU D 103
ILE D 120
1.73A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 6
THR A 556
SER A 682
SER A 681
VAL A 560
1.53A8.44
17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 7
SER C  15
VAL C  12
LEU A 437
ASP A 846
1.60A12.24

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
SER B 164
VAL B 160
LEU A 388
1.62A11.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.56A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
(SARS-CoV-2)		5 / 11
HIS A 347
CYH A 659
ILE A 632
MET A 629
VAL A 315
1.67A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.61A14.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
SER B 164
VAL B 160
LEU A 388
PRO B 183
1.56A19.10

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
SER A 681
VAL A 560
THR A 556
SER A 682
1.51A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 846
SER C  15
VAL C  12
LEU A 437
1.58A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.73A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 556
SER A 682
SER A 681
VAL A 560
1.52A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 12
LEU C1045
SER C1033
PHE C 909
GLN C1036
VAL C 860
1.66A10.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
THR A 760
ASP A 757
PRO A 845
VAL A 842
1.48A3.65
13.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 191
ASP H 158
PRO H 133
VAL H 164
1.58A13.73
20.47
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6nur NSP12
NSP8
(SARSr-CoV)		4 / 7
SER B 164
ASP B 163
VAL A 405
LEU A 544
1.33A10.34
20.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6nur NSP12
(SARSr-CoV)		4 / 6
THR A 556
SER A 682
SER A 681
VAL A 560
1.54A5.20
17.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6nus NSP12
(SARSr-CoV)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.67A15.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6nus NSP12
NSP8
(SARSr-CoV)		4 / 7
ASP A 377
PRO A 328
VAL A 675
LEU B 122
1.44A5.20
17.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
THR B  95
PRO B 217
VAL B  62
LEU B 223
1.32A2.57
13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 858
ASN C 955
VAL C1008
GLN C1011
ILE C 770
1.64A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A 524
ASN A 394
TYR A 396
TYR A 365
ILE A 358
1.71A12.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
THR C 778
ASP C 775
PRO C 863
VAL C 860
1.59A2.57
13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A 346
LEU A 255
ILE A 270
VAL A 276
ILE A 296
1.43A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vxs NSP3
(SARS-CoV-2)		5 / 11
LEU A 126
VAL A  49
LEU A 153
VAL A  35
ILE A  23
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C1063
SER C1051
PHE C 927
GLN C1054
ILE C 882
1.80A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B1049
VAL B1065
LEU B 806
ILE B 923
ILE B 931
1.55A9.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
SER C 967
ASP B 571
SER C 975
VAL C 976
1.50A2.76
13.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU A1049
VAL A1065
LEU A 806
ILE A 923
ILE A 931
1.52A9.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A1133
ASN A1135
ILE A1130
PHE A1089
TYR B 917
1.60A12.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 518
ARG C 328
PRO C 579
GLN C 564
ILE C 332
1.56A10.48
None
None
None
None
NAG  C1305 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.69A18.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.57A19.73
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.55A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
VAL H 207
SER H 120
ASP H 144
PRO H 119
1.77A17.16
17.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
SER H 120
ASP H 144
PRO H 119
VAL H 207
1.77A17.36
17.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
SER H 203
PRO H 119
VAL H 150
LEU H 170
1.48A17.36
17.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
SER H 177
ASP H 144
PRO H 119
VAL H 150
1.75A17.36
17.16
GOL  L 301 (-3.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
VAL H 150
LEU H 170
SER H 203
PRO H 119
1.53A17.16
17.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
VAL H 150
SER H 177
ASP H 144
PRO H 119
1.76A17.16
17.36
None
GOL  L 301 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
VAL H 150
SER H 177
ASP H 144
PRO H 119
1.75A17.16
17.36
None
GOL  L 301 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
SER H 120
ASP H 144
PRO H 119
VAL H 207
1.76A17.36
17.16
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
SER H 177
ASP H 144
PRO H 119
VAL H 150
1.77A17.36
17.16
GOL  L 301 (-3.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		5 / 11
LEU H 159
LEU H 189
ASN H 155
VAL H 211
ILE H 195
1.77A18.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w4h NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.58A19.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.46A12.50
18.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.45A18.60
12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w75 NSP16
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.54A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.51A17.22
11.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w75 NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.54A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A11.88
17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.53A11.88
17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.78A21.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.55A17.22
11.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
THR B  63
ASP B  61
PRO B  59
VAL B  57
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL B 165
TYR B 112
ILE B 123
PHE B 127
ILE B 151
1.78A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 6
VAL B  57
THR B  63
ASP B  61
PRO B  59
1.76A21.28
8.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
VAL B  57
THR B  63
ASP B  61
PRO B  59
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL C 165
TYR C 112
ILE C 123
PHE C 127
ILE C 151
1.67A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR A 251
ILE A 285
TYR A 296
GLU A 263
ILE A 300
1.45A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 351
ASN A 354
TYR A 356
TYR A 317
PHE A 372
1.52A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU B  98
VAL A   6
LEU A  14
ILE B 107
ILE A  39
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.30A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
VAL B 131
ILE B 120
TYR B 149
TYR B 138
1.65A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
TYR B 149
ILE B 132
TYR B 138
1.64A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wiq NSP8
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU D 352
LEU D 339
LEU D 291
ILE D 337
ILE D 357
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU E 352
LEU E 339
LEU E 291
ILE E 337
ILE E 357
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU B 352
LEU B 339
LEU B 291
ILE B 337
ILE B 357
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU F 352
LEU F 339
LEU F 291
ILE F 337
ILE F 357
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL B4295
LEU A6834
SER A6872
ASP A6873
1.42A
None
None
SAH  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL D4295
LEU C6834
SER C6872
ASP C6873
1.44A
None
None
SAH  C7102 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
SER C6872
ASP C6873
VAL D4295
LEU C6834
1.46A
SAH  C7102 (-4.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
ILE A6925
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
SER A6872
ASP A6873
VAL B4295
LEU A6834
1.46A
SAH  A7102 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wkq NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wkq NSP16
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR A 196
ASP A 324
SER A 274
LEU A 255
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR B 196
ASP B 324
SER B 274
LEU B 255
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER B 274
LEU B 201
THR B 196
ASP B 324
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER B 274
LEU B 255
THR B 196
ASP B 324
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR A 196
ASP A 324
SER A 274
LEU A 201
1.54A
None
None
None
EDO  A 405 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR B 196
ASP B 324
SER B 274
LEU B 201
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER A 274
LEU A 201
THR A 196
ASP A 324
1.58A
None
EDO  A 405 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER A 274
LEU A 255
THR A 196
ASP A 324
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A 268
LEU A 250
VAL A 202
LEU A 287
ILE A 200
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 126
VAL B  16
LEU B 160
MET B 171
ILE B  18
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C  83
HIS C  86
LEU C  88
LEU C  43
ILE C  23
1.71A
None
None
None
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  83
HIS A  86
LEU A  88
LEU A  43
ILE A  23
1.70A
None
None
None
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 126
VAL C  16
LEU C 160
MET C 171
ILE C  18
1.78A
APR  C 201 (-4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 126
VAL C  49
LEU C 153
VAL C  35
ILE C  23
1.79A
APR  C 201 (-4.9A)
APR  C 201 (-3.8A)
None
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP8
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wqd NSP7
NSP8
(SARS-CoV-2)		4 / 7
VAL A  53
LEU A  71
SER B 151
ASP B 101
1.58A
EDO  B 302 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU A  13
VAL A  58
LEU B 128
ILE A  39
ILE B 119
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.38A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  13
VAL C  58
LEU D 128
ILE C  39
ILE D 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  40
HIS C  36
LEU C  14
MET D  87
VAL A  11
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wqd NSP7
NSP8
(SARS-CoV-2)		4 / 7
SER B 151
ASP B 101
VAL A  53
LEU A  71
1.57A
None
None
EDO  B 302 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.38A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP8
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
TYR D 149
TYR D 138
1.72A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
SER A 180
PRO A 240
VAL A 205
LEU A 120
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
VAL A 205
LEU A 120
SER A 180
PRO A 240
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
TYR A 251
ILE A 285
TYR A 296
GLU A 263
ILE A 300
1.43A22.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
LEU A 162
LEU A 113
CYH A 155
MET A 169
VAL A 165
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.54A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU A  56
LEU A  28
VAL A  58
LEU B 103
ILE B 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL C  53
LEU C  71
SER D 151
ASP D 101
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
SER B 151
ASP B 101
VAL A  53
LEU A  71
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU C  13
VAL C  58
LEU D 128
ILE C  39
ILE D 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL A  53
LEU A  71
SER B 151
ASP B 101
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.29A21.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
SER D 151
ASP D 101
VAL C  53
LEU C  71
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.37A21.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 155
SER B  21
SER B   7
VAL B   5
1.72A
MLI  H 305 ( 4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H  11
LEU H 179
THR H 209
PRO H 206
1.41A
None
MLI  H 301 ( 4.9A)
None
DMS  H 303 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER B 124
ASP B 148
PRO B 123
VAL B 211
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
PRO H 171
SER H 181
VAL H 173
LEU L 142
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL B 154
LEU B 174
SER B 207
PRO B 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER B 181
ASP B 148
PRO B 123
VAL B 154
1.68A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 181
ASP H 148
PRO H 123
VAL H 154
1.73A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 211
SER H 124
ASP H 148
PRO H 123
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
VAL H 154
SER H 181
ASP H 148
PRO H 123
1.72A21.05
18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER H 207
PRO H 123
VAL H 154
LEU H 174
1.43A
None
None
None
MLI  H 304 (-4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
VAL B 154
SER B 181
ASP B 148
PRO B 123
1.65A21.05
18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 11
LEU B 163
LEU B 193
ASN B 159
VAL B 215
ILE B 199
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER B   7
VAL B   5
THR H 155
SER B  21
1.75A
None
None
MLI  H 305 ( 4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 179
THR H 116
PRO H 206
1.37A
None
MLI  H 301 ( 4.9A)
None
DMS  H 303 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
THR H 155
SER B  21
SER B   7
VAL B   5
1.74A18.18
21.05
MLI  H 305 ( 4.1A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER B 124
ASP B 148
PRO B 123
VAL B 211
1.75A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL B 211
SER B 124
ASP B 148
PRO B 123
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR B 116
PRO B 206
VAL B 154
LEU B 174
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR B 116
PRO B 206
VAL B 154
LEU B 179
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yla HEAVY CHAIN
(Homo
sapiens)		5 / 11
LEU H 163
LEU H 193
ASN H 159
VAL H 215
ILE H 199
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 174
SER H 207
PRO H 123
1.47A
None
MLI  H 304 (-4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL B 154
LEU B 179
THR B 116
PRO B 206
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
SER H 181
VAL H 173
LEU L 142
PRO H 171
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER B 207
PRO B 123
VAL B 154
LEU B 174
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER B   7
VAL B   5
THR H 155
SER B  21
1.70A21.05
18.18
None
None
MLI  H 305 ( 4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 116
PRO H 206
VAL H 154
LEU H 179
1.39A
None
DMS  H 303 ( 4.7A)
None
MLI  H 301 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 209
PRO H 206
VAL H  11
LEU H 179
1.46A
None
DMS  H 303 ( 4.7A)
None
MLI  H 301 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.77A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 174
SER H 207
PRO H 123
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 211
SER H 124
ASP H 148
PRO H 123
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 181
ASP H 148
PRO H 123
VAL H 154
1.70A17.61
20.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 116
PRO H 206
VAL H 154
LEU H 179
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
THR L 103
SER H  61
PRO L 101
SER H  63
1.41A10.33
20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER H 207
PRO H 123
VAL H 154
LEU H 174
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.73A17.61
20.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
THR H 116
PRO H 206
VAL H 154
LEU H 174
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 179
THR H 116
PRO H 206
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6ym0 HEAVY CHAIN
(Homo
sapiens)		5 / 11
LEU H 163
LEU H 193
ASN H 159
VAL H 215
ILE H 199
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
VAL H 211
SER H 124
ASP H 148
PRO H 123
1.80A20.64
17.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
VAL H 154
SER H 181
ASP H 148
PRO H 123
1.70A20.64
17.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 7
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
SER H 181
ASP H 148
PRO H 123
VAL H 154
1.73A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
SER B 181
VAL B 173
LEU C 142
PRO B 171
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
VAL H 211
SER H 124
ASP H 148
PRO H 123
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
THR H 116
PRO H 206
VAL H 154
LEU H 174
1.46A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
SER B 124
ASP B 148
PRO B 123
VAL B 211
1.78A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
PRO B 171
SER B 181
VAL B 173
LEU C 142
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 11
LEU B 163
LEU B 193
ASN B 159
VAL B 215
ILE B 199
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.76A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
VAL H 154
SER H 181
ASP H 148
PRO H 123
1.73A21.05
18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
SER H 124
ASP H 148
PRO H 123
VAL H 211
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
THR H 116
PRO H 206
VAL H 154
LEU H 179
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yor IGG H CHAIN
(Homo
sapiens)		5 / 11
LEU H 163
LEU H 193
ASN H 159
VAL H 215
ILE H 199
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
THR B 116
PRO B 206
VAL B 154
LEU B 179
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
THR B 116
PRO B 206
VAL B 154
LEU B 174
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
VAL B 154
SER B 181
ASP B 148
PRO B 123
1.73A21.05
18.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
SER B 207
PRO B 123
VAL B 154
LEU B 174
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
SER H 181
VAL H 173
LEU L 142
PRO H 171
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
PRO H 171
SER H 181
VAL H 173
LEU L 142
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
SER H 207
PRO H 123
VAL H 154
LEU H 174
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
VAL B 154
LEU B 174
SER B 207
PRO B 123
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 179
THR H 116
PRO H 206
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
SER B 181
ASP B 148
PRO B 123
VAL B 154
1.74A18.18
21.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 7
VAL H 154
LEU H 174
SER H 207
PRO H 123
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
PRO A  98
VAL A  96
ASN A  37
ILE A 106
ILE A 131
1.52A19.34
None
None
None
None
EDO  A 202 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
PRO E  98
VAL E  96
ASN E  37
ILE E 106
ILE E 131
1.53A19.34
None
None
None
None
EPE  E 202 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL A 398
LEU A 329
THR B 123
PRO B 121
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
SER B 164
VAL B 160
LEU A 388
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP8
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 846
SER C  15
VAL C  12
LEU A 437
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.26A22.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
TYR D 149
ILE D 132
TYR D 138
1.50A22.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.68A14.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  35
LEU C  28
VAL C  58
LEU D 122
ILE D 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.36A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
TYR D 149
ILE D 132
TYR D 138
1.70A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.24A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
SER A 672
VAL A 398
THR A 393
ASP A 390
1.54A17.28
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
HIS A 347
CYH A 659
ILE A 632
MET A 629
VAL A 315
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP7
(SARS-CoV-2)		4 / 7
SER C  25
VAL C  22
LEU C  55
SER C  26
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
LEU A 142
LEU A 212
CYH A 151
VAL A 182
ILE A 244
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
PHE D 147
TYR D 149
1.65A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 575
SER A 578
PHE A 480
ILE A 589
SER A 692
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  35
LEU C  28
VAL C  58
LEU D 122
ILE D 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
SER A 835
ASP A 833
PRO A 832
VAL A 880
1.73A8.44
17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
SER A 672
VAL A 398
THR A 393
ASP A 390
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
TYR D 149
TYR D 138
1.52A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.76A14.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
VAL A 557
THR A 687
SER A 681
ASP A 684
1.78A17.28
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
VAL A 330
LEU B  98
ILE A 539
MET A 666
ILE B 120
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL A 398
LEU A 329
THR B 123
PRO B 121
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
THR A 687
SER A 681
ASP A 684
VAL A 557
1.79A8.44
17.28
F86  P 102 (-3.6A)
None
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 387
LEU A 401
LEU B 122
ILE A 539
ILE B 120
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 142
LEU A 212
CYH A 151
VAL A 182
ILE A 244
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 687
SER A 681
ASP A 684
VAL A 557
1.74A
F86  P 102 (-3.6A)
None
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.22A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
SER A 681
VAL A 560
THR A 556
SER A 682
1.67A
None
U  T  10 ( 4.6A)
None
U  T  10 (-2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
SER A 681
VAL A 560
THR A 556
SER A 682
1.71A17.28
8.44
None
U  T  10 ( 4.6A)
None
U  T  10 (-2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.70A14.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 556
SER A 682
SER A 681
VAL A 560
1.68A
None
U  T  10 (-2.9A)
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU B  91
LEU B  98
VAL A 341
LEU A 366
ILE A 333
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 557
THR A 687
SER A 681
ASP A 684
1.77A
 U  T  10 ( 4.6A)
F86  P 102 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.77A
 U  P  17 ( 4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
THR A 556
SER A 682
SER A 681
VAL A 560
1.68A8.44
17.28
None
U  T  10 (-2.9A)
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.19A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
VAL A 557
THR A 687
SER A 681
ASP A 684
1.69A17.28
8.44
 U  T  10 ( 4.6A)
F86  P 102 (-3.6A)
None
None